Korsana Biosciences(KRSA)
$31.65+0.37 (+1.18%)
KRSA
Korsana Biosciences financials statements
$31.65
At close:+0.37 (+1.18%)
Want to see KRSA full AI Analyst Report?
Korsana Biosciences (KRSA) Ratios
281 Followers
Korsana Biosciences Ratios
KRSA's free cash flow for Q3 2026 was $-47.13M. For the 2026 fiscal year, KRSA's free cash flow was decreased by $-297.00K and operating cash flow was $-46.83M. See a summary of the company’s cash flow.
| Ratios | Dec 25 | Dec 24 | Dec 23 | Dec 22 | Dec 21 |
|---|---|---|---|---|---|
| Liquidity Ratios | |||||
| Current Ratio | 5.15 | 5.83 | 3.85 | 1.94 | 5.00 |
| Quick Ratio | 5.15 | 5.83 | 3.85 | 1.94 | 4.92 |
| Cash Ratio | 3.60 | 4.46 | 3.63 | 1.75 | 4.87 |
| Solvency Ratio | -3.92 | -4.22 | -2.49 | -5.77 | -4.62 |
| Operating Cash Flow Ratio | -3.68 | -5.98 | -10.18 | -5.32 | -3.29 |
| Short-Term Operating Cash Flow Coverage | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Net Current Asset Value | $ 3.73M | $ 3.50M | $ 5.94M | $ 7.19M | $ 44.37M |
| Leverage Ratios | |||||
| Debt-to-Assets Ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Debt-to-Equity Ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Debt-to-Capital Ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Long-Term Debt-to-Capital Ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Financial Leverage Ratio | 1.10 | 1.08 | 1.18 | 1.73 | 1.23 |
| Debt Service Coverage Ratio | 0.00 | 0.00 | 0.00 | 0.00 | -3365.13 |
| Interest Coverage Ratio | 0.00 | 0.00 | 0.00 | 0.00 | -3449.69 |
| Debt to Market Cap | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest Debt Per Share | 0.00 | 0.00 | 0.00 | 0.00 | 0.01 |
| Net Debt to EBITDA | 0.92 | 1.06 | 0.79 | 0.72 | 1.00 |
| Profitability Margins | |||||
| Gross Profit Margin | 100.00% | 100.00% | 0.00% | -1778.45% | 100.00% |
| EBIT Margin | -170.11% | -152.85% | 0.00% | -6242.42% | -1635.96% |
| EBITDA Margin | -170.11% | -152.85% | 0.00% | -6220.54% | -1621.75% |
| Operating Profit Margin | -239.78% | -181.40% | 0.00% | -6242.42% | -1662.50% |
| Pretax Profit Margin | -170.11% | -152.85% | 0.00% | -6143.43% | -1555.63% |
| Net Profit Margin | -170.11% | -152.85% | 0.00% | -14841.08% | -1555.63% |
| Continuous Operations Profit Margin | -170.11% | -152.85% | 0.00% | -6143.43% | -1555.63% |
| Net Income Per EBT | 100.00% | 100.00% | 41.79% | 241.58% | 100.00% |
| EBT Per EBIT | 70.94% | 84.26% | 97.24% | 98.41% | 93.57% |
| Return on Assets (ROA) | -35.33% | -31.93% | -39.35% | -243.81% | -87.05% |
| Return on Equity (ROE) | -38.83% | -34.54% | -46.62% | -421.72% | -107.05% |
| Return on Capital Employed (ROCE) | -54.74% | -40.99% | -114.73% | -177.38% | -114.40% |
| Return on Invested Capital (ROIC) | -54.74% | -40.99% | -114.73% | -177.38% | -114.40% |
| Return on Tangible Assets | -35.33% | -31.93% | -39.35% | -243.81% | -87.05% |
| Earnings Yield | -7.87% | -37.70% | -67.20% | -154.61% | -76.71% |
| Efficiency Ratios | |||||
| Receivables Turnover | 2.07 | 3.60 | 0.00 | 3.09 | 33.20 |
| Payables Turnover | 0.00 | 0.00 | 0.00 | 1.88 | 0.00 |
| Inventory Turnover | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Fixed Asset Turnover | 0.00 | 0.00 | 0.00 | 0.24 | 2.26 |
| Asset Turnover | 0.21 | 0.21 | 0.00 | 0.02 | 0.06 |
| Working Capital Turnover Ratio | 0.57 | 0.42 | 0.00 | 0.01 | 0.08 |
| Cash Conversion Cycle | 175.99 | 101.47 | 0.00 | -76.33 | 10.99 |
| Days of Sales Outstanding | 175.99 | 101.47 | 0.00 | 117.98 | 10.99 |
| Days of Inventory Outstanding | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Days of Payables Outstanding | 0.00 | 0.00 | 0.00 | 194.31 | 0.00 |
| Operating Cycle | 175.99 | 101.47 | 0.00 | 117.98 | 10.99 |
| Cash Flow Ratios | |||||
| Operating Cash Flow Per Share | -0.66 | -1.72 | -9.09 | -18.69 | -18.66 |
| Free Cash Flow Per Share | -0.66 | -1.72 | -9.09 | -18.69 | -18.66 |
| Dividend Paid and CapEx Coverage Ratio | 0.00 | 0.00 | 0.00 | 0.00 | -5216.71 |
| Capital Expenditure Coverage Ratio | 0.00 | 0.00 | 0.00 | 0.00 | -5216.71 |
| Operating Cash Flow Coverage Ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Cash Flow to Sales Ratio | -1.60 | -2.17 | 0.00 | -136.74 | -11.00 |
| Free Cash Flow Yield | -7.39% | -53.44% | -271.25% | -142.45% | -54.25% |
| Valuation Ratios | |||||
| Price-to-Earnings (P/E) Ratio | -1.26 | -2.65 | -1.49 | -0.65 | -1.30 |
| Price-to-Sales (P/S) Ratio | 21.61 | 4.05 | 0.00 | 95.99 | 20.28 |
| Price-to-Book (P/B) Ratio | 4.93 | 0.92 | 0.69 | 2.73 | 1.40 |
| Price-to-Free Cash Flow (P/FCF) Ratio | -13.52 | -1.87 | -0.37 | -0.70 | -1.84 |
| Price-to-Operating Cash Flow Ratio | -13.52 | -1.87 | -0.37 | -0.70 | -1.84 |
| Price-to-Earnings Growth (PEG) Ratio | -0.00 | 0.03 | 0.03 | 0.03 | 0.03 |
| Enterprise Value Multiple | -11.79 | -1.60 | -0.03 | -0.82 | -0.25 |
| Enterprise Value | 41.58M | 4.88M | 261.30K | 15.13M | 13.37M |
| EV to EBITDA | -11.79 | -1.60 | -0.03 | -0.82 | -0.25 |
| EV to Sales | 20.05 | 2.44 | 0.00 | 50.94 | 4.03 |
| EV to Free Cash Flow | -12.55 | -1.13 | -0.01 | -0.37 | -0.37 |
| EV to Operating Cash Flow | -12.55 | -1.13 | -0.01 | -0.37 | -0.37 |
| Tangible Book Value Per Share | 1.80 | 3.51 | 4.83 | 4.81 | 24.65 |
| Shareholders’ Equity Per Share | 1.80 | 3.51 | 4.83 | 4.81 | 24.65 |
| Tax and Other Ratios | |||||
| Effective Tax Rate | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Revenue Per Share | 0.41 | 0.79 | 0.00 | 0.14 | 1.70 |
| Net Income Per Share | -0.70 | -1.21 | -2.25 | -20.28 | -26.39 |
| Tax Burden | 1.00 | 1.00 | 0.42 | 2.42 | 1.00 |
| Interest Burden | 1.00 | 1.00 | 1.31 | 0.98 | 0.95 |
| Research & Development to Revenue | 0.46 | 0.14 | 0.00 | 20.13 | 11.34 |
| SG&A to Revenue | 2.94 | 2.67 | 0.00 | 43.29 | 6.21 |
| Stock-Based Compensation to Revenue | 0.21 | 0.31 | 0.00 | 0.00 | 2.89 |
| Income Quality | 0.94 | 1.42 | 1.69 | 2.23 | 0.71 |
Currency in USD
